Conditions: Anti- VGF Inhibitor Diabetic Macular Edema Diabetic Retinopathy
Keywords: pegaptanib sodium diabetic macular edema
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 46
Healthy volunteers: no

Brief summary:
This study will asses sthe safety of pegaptanib sodium in patients with diabetic macular edema. The hypothesis is that pegaptanib is safe and efficacious in patients with diabetic macular edema.

Detailed description:

Arms:
arm 1: all patients will receive pegaptanib sodium

Interventions: intervention 1: pegaptanib sodium
Intervention descriptions: intervention 1: Upon enrollment, all subjects will be treated in the study eye with pegaptanib sodium 0.3 mg at the investigators' discretion based on visual acuity assessment up to a maximum of 48 weeks. The minimum dosing interval between injections will be at least 6 weeks.

Protocol document: